Patents by Inventor Christopher Gordon Tate

Christopher Gordon Tate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11339383
    Abstract: The invention provides a mutant of a parent heterotrimeric G protein alpha (G?) subunit, which mutant (i) lacks at least one helix of the helical domain of the parent G? subunit; (ii) is capable of binding to a GPCR in the absence of a heterotrimeric G protein beta (G?) subunit and a heterotrimeric G protein gamma (G?) subunit; and (iii) has an amino acid sequence that contains one or more mutations compared to the amino acid sequence of the parent heterotrimeric G? subunit, which mutations are selected from a deletion, a substitution and an insertion.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: May 24, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Byron Carpenter, Andrew Leslie, Rony Nehmé, Christopher Gordon Tate, Antony Warne
  • Publication number: 20210148939
    Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 20, 2021
    Applicant: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
  • Publication number: 20210061882
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: May 11, 2020
    Publication date: March 4, 2021
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Patent number: 10738287
    Abstract: The invention provides a mutant of a parent heterotrimeric G protein alpha (G?) subunit, which mutant (i) lacks at least one helix of the helical domain of the parent G? subunit; (ii) is capable of binding to a GPCR in the absence of a heterotrimeric G protein beta (G?) subunit and a heterotrimeric G protein gamma (G?) subunit; and (iii) has an amino acid sequence that contains one or more mutations compared to the amino acid sequence of the parent heterotrimeric G? subunit, which mutations are selected from a deletion, a substitution and an insertion.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 11, 2020
    Assignee: Heptares Therapeutics Limited
    Inventors: Byron Carpenter, Andrew Leslie, Rony Nehmé, Christopher Gordon Tate, Antony Warne
  • Publication number: 20200231949
    Abstract: The invention provides a mutant of a parent heterotrimeric G protein alpha (G?) subunit, which mutant (i) lacks at least one helix of the helical domain of the parent G? subunit; (ii) is capable of binding to a GPCR in the absence of a heterotrimeric G protein beta (G?) subunit and a heterotrimeric G protein gamma (G?) subunit; and (iii) has an amino acid sequence that contains one or more mutations compared to the amino acid sequence of the parent heterotrimeric G? subunit, which mutations are selected from a deletion, a substitution and an insertion.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 23, 2020
    Inventors: Byron Carpenter, Andrew Leslie, Rony Nehmé, Christopher Gordon Tate, Antony Warne
  • Publication number: 20200190161
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Application
    Filed: November 25, 2019
    Publication date: June 18, 2020
    Applicant: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Patent number: 10544202
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: January 28, 2020
    Assignee: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Publication number: 20190241644
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: December 10, 2018
    Publication date: August 8, 2019
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20190094247
    Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
    Type: Application
    Filed: October 4, 2018
    Publication date: March 28, 2019
    Applicant: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
  • Publication number: 20190032033
    Abstract: The invention provides a mutant of a parent heterotrimeric G protein alpha (G?) subunit, which mutant (i) lacks at least one helix of the helical domain of the parent G? subunit; (ii) is capable of binding to a GPCR in the absence of a heterotrimeric G protein beta (G?) subunit and a heterotrimeric G protein gamma (G?) subunit; and (iii) has an amino acid sequence that contains one or more mutations compared to the amino acid sequence of the parent heterotrimeric G? subunit, which mutations are selected from a deletion, a substitution and an insertion.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Inventors: Byron Carpenter, Andrew Leslie, Rony Nehmé, Christopher Gordon Tate, Antony Warne
  • Patent number: 10126313
    Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: November 13, 2018
    Assignee: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
  • Publication number: 20180282395
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Application
    Filed: February 12, 2018
    Publication date: October 4, 2018
    Applicant: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Patent number: 9932385
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallization studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 3, 2018
    Assignee: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Publication number: 20180086814
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: September 26, 2017
    Publication date: March 29, 2018
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20160052991
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: August 26, 2015
    Publication date: February 25, 2016
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Publication number: 20160031966
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Applicant: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Patent number: 9081020
    Abstract: A method for selecting a membrane protein with increased stability, the method comprising: a) providing one or more mutants of a parent membrane protein in a membrane-containing composition, wherein the one or more mutants are exposed to an amount of a membrane destabilizing agent which is effective to destabilize the parent membrane protein in-situ, b) determining whether the or each mutant membrane protein has increased stability with respect to its structure and/or a biological activity compared to the stability of the parent membrane protein with respect to its structure and/or the same biological activity, and c) selecting the one or more mutants which have increased stability compared to the stability of the parent membrane protein.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 14, 2015
    Assignee: Heptares Therapeutics Limited
    Inventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Edward Christopher Hulme
  • Patent number: 8785135
    Abstract: The present invention relates in some aspects to mutant G protein coupled receptors (GPCRs) and methods for selecting those with increased stability. In certain aspects, the invention relates to the selection and preparation of mutant GPCRs which have increased stability under a particular condition compared to their respective parent proteins.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: July 22, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Patent number: 8748182
    Abstract: Aspects of the invention relate to methods of producing a mutant GPCR with increased stability relative to its parent GPCR.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: June 10, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Jonathan Richard Heal, Richard Henderson, Christopher Gordon Tate, Malcolm Peter Weir
  • Patent number: 8703915
    Abstract: A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a parent GPCR, wherein (i) the one or more mutations are located within a window of/plus or minus 5 residues, where/is the position of amino acid residue 2.46 in the parent GPCR when the parent GPCR is a Class 1 GPCR, or where/is the position of an equivalent amino acid residue in the parent GPCR when the parent GPCR is a Class 2 or 3 GPCR, and/or (ii) the one or more mutations are located within an amino acid sequence of transmembrane helix 7 in the parent GPCR which amino acid sequence interacts with the window of/plus or minus 5 residues, to provide one or more mutants of the parent GPCR with increased stability.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: April 22, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Seyed Ali Jazayeri-Dezfuly, Guillaume Pierre Lebon, Fiona Hamilton Marshall, Christopher Gordon Tate, Nathan Robertson